Ines Macias‐Perez - Concepedia

Author

Ines Macias‐Perez

Tennessee Oncology

Also Known As

I MACIASPEREZ, Ines M. Macias-Perez, Ines M. Macias‐Perez, Ines Macias-Perez, Ines Macias‐Perez, Inés M. Macias-Pérez

Publications

732

Citations

H-Index

Concepts

All Affiliations

Tennessee Oncology Vanderbilt University Medical Center Cumberland Pharmaceuticals (United States)Sarah Cannon Vanderbilt University

About

Ines Macias‐Perez is an author at Tennessee Oncology specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	236
2	Health Sciences	2	2	191
3	Cell Biology	2	2	208
4	Immunology	2	2	39
5	Biochemistry	1	1	180

Ines Macias‐Perez

Publications

663

Citations

H-Index

Page 1

	Year	Citations
Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids Ambra Pozzi, Ines Macias‐Perez, Tristin D. Abair, Journal of Biological Chemistry Lipid AnalysisChemoprevention StrategyLipid PeroxidationP38 MapkCell Proliferation	2005	180
Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation Ambra Pozzi, Xuexian Yan, Ines Macias‐Perez, Journal of Biological Chemistry	2004	149
Prostaglandin E2-EP4 Receptor Promotes Endothelial Cell Migration via ERK Activation and Angiogenesis in Vivo Reena Rao, Reyadh Redha, Ines Macias‐Perez, Journal of Biological Chemistry	2007	130
Loss of Integrin α1β1 Ameliorates Kras-Induced Lung Cancer Ines Macias‐Perez, Corina M. Borza, Xiwu Chen, Cancer Research	2008	45
Fewer adverse effects associated with a modified two-bag intravenous acetylcysteine protocol compared to traditional three-bag regimen in paracetamol overdose Lars E. Schmidt, Ditlev N. Rasmussen, Tonny Studsgaard Petersen, Clinical Toxicology	2018	38
Mouse EP3 α, β, and γ Receptor Variants Reduce Tumor Cell Proliferation and Tumorigenesis in Vivo Ines Macias‐Perez, Roy Zent, Monica Carmosino, Journal of Biological Chemistry Mouse Ep3 αMedicineImmunologyCancer Cell BiologyCancer Genetics	2008	28
Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site John D. Hainsworth, David R. Spigel, Howard A. Burris, Cancer	2010	27
A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Ian W. Flinn, William N. Harwin, Ines Macias‐Perez, Blood	2011	21
Antagonism of the Thromboxane‐Prostanoid Receptor as a Potential Therapy for Cardiomyopathy of Muscular Dystrophy James West, Cristi L. Galindo, Kyung-Soo Kim, Journal of the American Heart Association Molecular PharmacologyCardiomyopathyHeart FailureMolecular PhysiologyTpr Antagonism	2019	17
Intravenous Ibuprofen Reduces Opioid Consumption During the Initial 48 Hours After Injury in Orthopedic Trauma Patients Russell D. Weisz, Alexander A. Fokin, Vivian Lerner, Journal of Orthopaedic Trauma	2020	17

Page 1